Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | VIR |
---|---|---|
09:32 ET | 8241 | 8.8001 |
09:34 ET | 804 | 8.81 |
09:36 ET | 4447 | 8.8017 |
09:38 ET | 19311 | 8.69 |
09:39 ET | 3650 | 8.77 |
09:41 ET | 5527 | 8.74 |
09:43 ET | 7175 | 8.83 |
09:45 ET | 2131 | 8.8475 |
09:48 ET | 14417 | 8.81 |
09:50 ET | 7047 | 8.86 |
09:52 ET | 3065 | 8.8701 |
09:54 ET | 641 | 8.9 |
09:56 ET | 4634 | 8.88 |
09:57 ET | 628 | 8.87 |
09:59 ET | 3134 | 8.845 |
10:01 ET | 2333 | 8.83 |
10:03 ET | 6229 | 8.86 |
10:06 ET | 997 | 8.8564 |
10:08 ET | 1728 | 8.85 |
10:10 ET | 1345 | 8.84 |
10:12 ET | 5977 | 8.88 |
10:14 ET | 2463 | 8.89 |
10:15 ET | 3249 | 8.89 |
10:17 ET | 670 | 8.87 |
10:19 ET | 4170 | 8.895 |
10:21 ET | 1589 | 8.88 |
10:24 ET | 1596 | 8.9 |
10:26 ET | 2029 | 8.88 |
10:28 ET | 6325 | 8.8902 |
10:30 ET | 1993 | 8.88 |
10:32 ET | 393 | 8.881 |
10:33 ET | 5515 | 8.87 |
10:35 ET | 600 | 8.86 |
10:37 ET | 3652 | 8.86 |
10:39 ET | 316 | 8.86 |
10:42 ET | 5083 | 8.84 |
10:44 ET | 900 | 8.85 |
10:46 ET | 621 | 8.8379 |
10:48 ET | 200 | 8.85 |
10:50 ET | 6867 | 8.8475 |
10:51 ET | 700 | 8.85 |
10:53 ET | 5123 | 8.84 |
10:57 ET | 200 | 8.84 |
11:00 ET | 7916 | 8.77 |
11:02 ET | 7929 | 8.755 |
11:04 ET | 24546 | 8.79 |
11:06 ET | 1643 | 8.79 |
11:08 ET | 1470 | 8.79 |
11:09 ET | 6783 | 8.815 |
11:11 ET | 1792 | 8.84 |
11:13 ET | 7206 | 8.85 |
11:15 ET | 5619 | 8.88 |
11:18 ET | 5400 | 8.86 |
11:20 ET | 1300 | 8.8687 |
11:22 ET | 1940 | 8.83 |
11:24 ET | 800 | 8.8 |
11:26 ET | 534 | 8.8 |
11:27 ET | 2044 | 8.8 |
11:29 ET | 1012 | 8.8 |
11:31 ET | 4205 | 8.8 |
11:33 ET | 500 | 8.8 |
11:36 ET | 424 | 8.7952 |
11:38 ET | 2445 | 8.79 |
11:40 ET | 3252 | 8.7875 |
11:42 ET | 3254 | 8.82 |
11:44 ET | 2099 | 8.82 |
11:45 ET | 224 | 8.82 |
11:49 ET | 3113 | 8.81 |
11:51 ET | 2449 | 8.81 |
11:54 ET | 2160 | 8.8 |
11:56 ET | 7274 | 8.84 |
11:58 ET | 916 | 8.85 |
12:00 ET | 2081 | 8.84 |
12:02 ET | 1400 | 8.845 |
12:03 ET | 3138 | 8.84 |
12:05 ET | 620 | 8.84 |
12:07 ET | 2022 | 8.84 |
12:09 ET | 174 | 8.84 |
12:12 ET | 5480 | 8.87 |
12:14 ET | 700 | 8.86 |
12:16 ET | 1514 | 8.85 |
12:18 ET | 1000 | 8.85 |
12:20 ET | 1090 | 8.85 |
12:21 ET | 6794 | 8.92 |
12:23 ET | 1350 | 8.91 |
12:25 ET | 200 | 8.91 |
12:27 ET | 1500 | 8.9 |
12:30 ET | 1600 | 8.88 |
12:32 ET | 6131 | 8.91 |
12:34 ET | 2956 | 8.92 |
12:36 ET | 3504 | 8.9 |
12:38 ET | 200 | 8.91 |
12:39 ET | 200 | 8.89 |
12:41 ET | 4402 | 8.93 |
12:43 ET | 1000 | 8.94 |
12:45 ET | 623 | 8.9476 |
12:48 ET | 590 | 8.95 |
12:50 ET | 600 | 8.93 |
12:52 ET | 9908 | 8.94 |
12:54 ET | 1260 | 8.93 |
12:56 ET | 310 | 8.94 |
12:57 ET | 3370 | 8.94 |
12:59 ET | 3649 | 8.94 |
01:01 ET | 865 | 8.93 |
01:03 ET | 700 | 8.92 |
01:06 ET | 2707 | 8.94 |
01:08 ET | 1000 | 8.93 |
01:10 ET | 500 | 8.94 |
01:12 ET | 1000 | 8.93 |
01:14 ET | 3681 | 8.95 |
01:15 ET | 1699 | 8.935 |
01:17 ET | 383 | 8.93 |
01:19 ET | 2172 | 8.93 |
01:21 ET | 400 | 8.92 |
01:24 ET | 5831 | 8.94 |
01:26 ET | 2721 | 8.92 |
01:28 ET | 200 | 8.94 |
01:30 ET | 790 | 8.94 |
01:32 ET | 651 | 8.94 |
01:33 ET | 9019 | 8.9 |
01:35 ET | 316 | 8.92 |
01:37 ET | 2664 | 8.93 |
01:39 ET | 1214 | 8.93 |
01:42 ET | 1200 | 8.94 |
01:44 ET | 5401 | 8.97 |
01:46 ET | 2244 | 8.99 |
01:50 ET | 7523 | 9.0286 |
01:51 ET | 300 | 9.02 |
01:53 ET | 9230 | 8.97 |
01:55 ET | 3954 | 8.97 |
01:57 ET | 3432 | 8.99 |
02:00 ET | 1033 | 8.99 |
02:02 ET | 400 | 8.99 |
02:04 ET | 2404 | 8.985 |
02:06 ET | 1421 | 8.98 |
02:08 ET | 19735 | 9.01 |
02:09 ET | 1783 | 9 |
02:11 ET | 2576 | 9.01 |
02:13 ET | 400 | 9 |
02:15 ET | 408 | 8.99 |
02:18 ET | 1420 | 8.98 |
02:20 ET | 3639 | 8.99 |
02:22 ET | 3244 | 9.01 |
02:24 ET | 100 | 9.01 |
02:26 ET | 10960 | 9.05 |
02:27 ET | 6387 | 9.01 |
02:29 ET | 390 | 9.02 |
02:31 ET | 1093 | 9.02 |
02:33 ET | 1791 | 9.04 |
02:36 ET | 702 | 9.03 |
02:38 ET | 700 | 9.01 |
02:40 ET | 1004 | 9 |
02:42 ET | 2491 | 9.01 |
02:44 ET | 900 | 9.02 |
02:45 ET | 2495 | 9.02 |
02:47 ET | 355 | 9.02 |
02:49 ET | 654 | 9.02 |
02:51 ET | 1308 | 9.01 |
02:54 ET | 1630 | 9 |
02:56 ET | 7229 | 8.97 |
02:58 ET | 5471 | 8.975 |
03:00 ET | 2536 | 8.97 |
03:02 ET | 4017 | 8.97 |
03:03 ET | 1763 | 8.94 |
03:05 ET | 787 | 8.93 |
03:07 ET | 3182 | 8.94 |
03:09 ET | 2906 | 8.94 |
03:12 ET | 667 | 8.95 |
03:14 ET | 3239 | 8.95 |
03:16 ET | 1744 | 8.94 |
03:18 ET | 3231 | 8.93 |
03:20 ET | 1211 | 8.93 |
03:21 ET | 12585 | 8.96 |
03:23 ET | 790 | 8.95 |
03:25 ET | 2350 | 8.95 |
03:27 ET | 2850 | 8.92 |
03:30 ET | 11854 | 8.925 |
03:32 ET | 2054 | 8.91 |
03:34 ET | 1050 | 8.91 |
03:36 ET | 7484 | 8.91 |
03:38 ET | 3980 | 8.9 |
03:39 ET | 6683 | 8.905 |
03:41 ET | 4482 | 8.9 |
03:43 ET | 12732 | 8.915 |
03:45 ET | 3791 | 8.919 |
03:48 ET | 7340 | 8.92 |
03:50 ET | 8635 | 8.93 |
03:52 ET | 12265 | 8.935 |
03:54 ET | 8035 | 8.97 |
03:56 ET | 26595 | 8.95 |
03:57 ET | 22462 | 8.93 |
03:59 ET | 167204 | 8.95 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Vir Biotechnology Inc | 1.2B | -2.2x | --- |
Nurix Therapeutics Inc | 1.1B | -7.9x | --- |
Prothena Corporation PLC | 1.1B | -6.0x | --- |
Immatics NV | 1.3B | -11.9x | --- |
Silence Therapeutics PLC | 882.6M | -16.6x | --- |
Ardelyx Inc | 1.4B | -20.4x | --- |
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.2B |
---|---|
Revenue (TTM) | $79.6M |
Shares Outstanding | 136.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.47 |
EPS | $-4.01 |
Book Value | $11.80 |
P/E Ratio | -2.2x |
Price/Sales (TTM) | 15.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -780.18% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.